Clover initiates GLP studies on SCB-313 (Trail-Trimer) at National Shanghai Center for New Drug Safety Evaluation and Research.

CHENGDU, CHINA, February 19, 2016 — Clover initiated GLP studies on its leading anti-cancer trimeric biologic, SCB-313 (Trail-Trimer) at National Shanghai Center for New Drug Safety Evaluation and Research.   Funded by multiple grants from the central government and designed with the patented Trimer-Tag technology, SCB-313 is a first-in-class, disulfide bond-linked trimeric Trail (Apo2L) produced from CHO cells.  Unliked the bacterially produced ligand,  SCB-313 is highly stable and glycosylated homo-trimer with more favorable PK and PD profiles.